Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
出版年份 2022 全文链接
标题
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
作者
关键词
-
出版物
mAbs
Volume 14, Issue 1, Pages -
出版商
Informa UK Limited
发表日期
2022-02-28
DOI
10.1080/19420862.2022.2031483
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells
- (2021) Shuai Wang et al. CELL RESEARCH
- SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment
- (2021) Nahed Abdel-Haq et al. EUROPEAN JOURNAL OF PEDIATRICS
- Antibodies to watch in 2021
- (2021) Hélène Kaplon et al. mAbs
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
- (2021) C. Garrett Rappazzo et al. SCIENCE
- Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
- (2021) Paul-Albert Koenig et al. SCIENCE
- Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
- (2021) Zhiqiang Ku et al. Nature Communications
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm
- (2021) Alexandra Pum et al. Biomolecules
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
- (2021) Emanuele Andreano et al. CELL
- High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2
- (2021) Bernard Vanhove et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- An overview of some potential immunotherapeutic options against COVID-19
- (2021) Maryam Bayat et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Efficacy and tolerability of bevacizumab in patients with severe Covid-19
- (2021) Jiaojiao Pang et al. Nature Communications
- Elevated P-Selectin in Severe Covid-19: Considerations for therapeutic options
- (2021) Chiara Agrati et al. Mediterranean Journal of Hematology and Infectious Diseases
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
- (2021) Naveenchandra Suryadevara et al. CELL
- Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
- (2021) Raoul De Gasparo et al. NATURE
- Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
- (2021) William N. Voss et al. SCIENCE
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
- (2021) Yu Guo et al. Nature Communications
- IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
- (2021) Isabella Quinti et al. Frontiers in Cellular and Infection Microbiology
- Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
- (2021) Deyong Song et al. Communications Biology
- Tackling COVID-19 with neutralizing monoclonal antibodies
- (2021) Davide Corti et al. CELL
- A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
- (2021) Laura A. VanBlargan et al. IMMUNITY
- Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
- (2021) Ruoke Wang et al. IMMUNITY
- In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
- (2021) Rita E. Chen et al. NATURE
- Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
- (2021) Zhiqiang Ku et al. NATURE
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
- (2021) Matthew McCallum et al. SCIENCE
- Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
- (2021) Kathryn M. Hastie et al. SCIENCE
- Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
- (2021) Hyeseon Cho et al. Science Translational Medicine
- COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
- (2021) Daniele Focosi et al. Viruses-Basel
- Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2021) Sandro Halwe et al. Viruses-Basel
- A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
- (2021) Yanyun Du et al. Nature Communications
- Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
- (2021) Yu Kaku et al. Cell Reports
- A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
- (2021) Federico Bertoglio et al. Cell Reports
- Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
- (2021) Fabian Bohländer et al. Frontiers in Immunology
- Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?
- (2021) Yalcin Pisil et al. Pathogens
- Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
- (2021) Vincent Dussupt et al. NATURE IMMUNOLOGY
- Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG
- (2021) Lin Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters
- (2021) Xueqiao Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection
- (2021) Pragya D. Yadav et al. Viruses-Basel
- Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
- (2021) Tingting Li et al. Nature Communications
- A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
- (2021) Xilin Wu et al. Cell Reports
- Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
- (2021) Bailey B. Banach et al. Cell Reports
- The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines
- (2021) Renee W. Y. Chan et al. Frontiers in Immunology
- A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2
- (2021) Qian Zhang et al. Infectious Diseases and Therapy
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
- (2020) Xiaolong Tian et al. Emerging Microbes & Infections
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
- (2020) Xiangyu Chen et al. Cellular & Molecular Immunology
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
- (2020) Li Guo et al. CLINICAL INFECTIOUS DISEASES
- Compassionate use of hzVSF‐v13 in two patients with severe COVID‐19
- (2020) Chang Kyung Kang et al. JOURNAL OF MEDICAL VIROLOGY
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Antibody responses to SARS-CoV-2 in patients with COVID-19
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- A lesson from a saboteur: High‐MW kininogen impact in coronavirus‐induced disease 2019
- (2020) Chiara Colarusso et al. BRITISH JOURNAL OF PHARMACOLOGY
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
- (2020) Yunlong Cao et al. CELL
- Tocilizumab for treatment of mechanically ventilated patients with COVID-19
- (2020) Emily C Somers et al. CLINICAL INFECTIOUS DISEASES
- Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications
- (2020) Subramanian Loganathan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2020) Wafaa B. Alsoussi et al. JOURNAL OF IMMUNOLOGY
- Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
- (2020) Ahmed Yaqinuddin et al. MEDICAL HYPOTHESES
- Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
- (2020) Julien Carvelli et al. NATURE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
- (2020) Daming Zhou et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
- (2020) Zhe Lv et al. SCIENCE
- Distinct conformational states of SARS-CoV-2 spike protein
- (2020) Yongfei Cai et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Broad neutralization of SARS-related viruses by human monoclonal antibodies
- (2020) Anna Z. Wec et al. SCIENCE
- Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
- (2020) Olivier Garraud TRANSFUSION AND APHERESIS SCIENCE
- Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report
- (2020) Gaurang Vaidya et al. TRANSPLANTATION PROCEEDINGS
- ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial
- (2020) Tom Wilkinson et al. Trials
- Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
- (2020) Tomás Palanques-Pastor et al. European Journal of Hospital Pharmacy-Science and Practice
- SARS-CoV-2 viral load predicts COVID-19 mortality
- (2020) Elisabet Pujadas et al. Lancet Respiratory Medicine
- Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
- (2020) Aldo Bonaventura et al. Frontiers in Immunology
- GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study
- (2020) Zelalem Temesgen et al. MAYO CLINIC PROCEEDINGS
- COVID-19 antibodies on trial
- (2020) Laura DeFrancesco NATURE BIOTECHNOLOGY
- Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
- (2020) M. Alejandra Tortorici et al. SCIENCE
- A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
- (2020) Monir Ejemel et al. Nature Communications
- Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
- (2020) Xiaojing Chi et al. Nature Communications
- FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
- (2020) Sylwester Drożdżal et al. DRUG RESISTANCE UPDATES
- Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
- (2020) Alexandra Schäfer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
- (2020) Jéromine Klingler et al. JOURNAL OF INFECTIOUS DISEASES
- Enhanced SARS-CoV-2 neutralization by dimeric IgA
- (2020) Zijun Wang et al. Science Translational Medicine
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
- Blockage of interleukin-1β with canakinumab in patients with Covid-19
- (2020) Lorenza Landi et al. Scientific Reports
- Exploiting Nanobodies’ Singular Traits
- (2018) Jessica R. Ingram et al. Annual Review of Immunology
- Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)
- (2018) Tobias Welte et al. INTENSIVE CARE MEDICINE
- Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
- (2018) Bushra Husain et al. BIODRUGS
- Nanobodies as therapeutics: big opportunities for small antibodies
- (2016) Sophie Steeland et al. DRUG DISCOVERY TODAY
- Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults
- (2015) Bindiya Bagga et al. JOURNAL OF INFECTIOUS DISEASES
- Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus
- (2015) Tadaki Suzuki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions
- (2014) William Kelton et al. CHEMISTRY & BIOLOGY
- IgM levels in plasma predict outcome in severe pandemic influenza
- (2013) Mar Justel et al. JOURNAL OF CLINICAL VIROLOGY
- A Systematic Review of Anti-Rotavirus Serum IgA Antibody Titer as a Potential Correlate of Rotavirus Vaccine Efficacy
- (2013) Manish Patel et al. JOURNAL OF INFECTIOUS DISEASES
- Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults
- (2013) Akira Ainai et al. Human Vaccines & Immunotherapeutics
- Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
- (2012) Elly van Riet et al. VACCINE
- Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
- (2012) Thomas R. Hird et al. PLoS Pathogens
- Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design
- (2011) Enrico L. DiGiammarino et al. mAbs
- Location of secretory component on the Fc edge of dimeric IgA1 reveals insight into the role of secretory IgA1 in mucosal immunity
- (2008) A Bonner et al. Mucosal Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started